Systemic Sclerosis Ssc clinical trials

Explore recruiting systemic sclerosis ssc clinical trials.

Recruiting systemic sclerosis ssc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Sclerosis Ssc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

Spain, Germany, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and other connective tissue diseases (CTD)

Greece, Denmark, Italy, Finland, Spain, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

France

Therapeutic exploratory (Phase II) EU CTIS Study details

CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis

Poland, Germany, Spain, Norway, Netherlands, Denmark +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Systemic Sclerosis Ssc trials by city

Systemic Sclerosis Ssc in Toronto Systemic Sclerosis Ssc in Vancouver Systemic Sclerosis Ssc in Montreal Systemic Sclerosis Ssc in Calgary Systemic Sclerosis Ssc in Edmonton Systemic Sclerosis Ssc in Ottawa Systemic Sclerosis Ssc in Winnipeg Systemic Sclerosis Ssc in Quebec City Systemic Sclerosis Ssc in Hamilton Systemic Sclerosis Ssc in Kitchener Systemic Sclerosis Ssc in London Systemic Sclerosis Ssc in Halifax Systemic Sclerosis Ssc in New York Systemic Sclerosis Ssc in Los Angeles Systemic Sclerosis Ssc in Chicago Systemic Sclerosis Ssc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease